Navigation Links
Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
Date:11/6/2008

- Voreloxin Demonstrates Promising Clinical Activity in Patients with

Difficult-to-Treat Cancers -

SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) presented data from three clinical trials of the company's lead drug candidate, voreloxin (formerly SNS-595), at the Chemotherapy Foundation Symposium held in New York on November 4-8. Data previously presented from Phase 1 and Phase 1b/2 studies in patients with acute myeloid leukemia (AML) showed that preliminary clinical responses were observed in the relapsed/refractory AML population and the data supports further clinical development for voreloxin both as a single agent and in combination with cytarabine. Preliminary efficacy results previously presented from an ongoing Phase 2 trial demonstrate single agent activity of voreloxin in advanced platinum-resistant ovarian cancer and that the drug is generally well tolerated in this difficult-to-treat patient population.

"We believe that voreloxin has the potential to change the standard of care in AML and platinum-resistant ovarian cancer and look forward to reporting updated results of our AML trials at ASH," said Daniel Swisher, Chief Executive Officer, Sunesis Pharmaceuticals. "Our goal is to advance voreloxin into a pivotal trial in AML by the end of 2009."

Phase 1 and 1b/2 Studies of Voreloxin in AML

Data presented from a completed Phase 1 dose escalation trial of voreloxin as a single agent in acute leukemias (N=73) showed that single agent voreloxin was generally well tolerated, with the most frequently observed dose limited toxicity (DLT) being reversible grade 3/4 oral mucositis. The researchers concluded that single agent a
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
8. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
9. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
10. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
11. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Inc. (NASDAQ: DEPO ) today announced that it will ... Conference in New York City . ... am EST (5:00 am PST) on Tuesday December 2, 2014.  The ... the Investor Relations page of the Depomed website at www.depomed.com ... days on the company,s website. About Depomed ...
(Date:11/21/2014)... Nov. 21, 2014  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... previously announced underwritten public offering of $50,000,000 of shares ... registration statement. The offering will consist of 49,751,244 shares ... $1.005 per share.  Lexicon has also granted the underwriters ... shares of common stock.  All of the shares in ...
(Date:11/18/2014)... LOS ANGELES , Nov. 18, 2014 /PRNewswire/ ... technology development, patient engagement and study recruitment – ... platform, called Sangre, to help Pfizer Inc. find ... Pain (CIP) and their family members to participate ... help potentially identify DNA mutations and hopefully aid ...
Breaking Medicine Technology:Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3Sanguine's Mobile Application to Assist Recruitment for Pfizer Inc. Chronic Pain Research 2
(Date:11/21/2014)... Grants Pass, OR (PRWEB) November 21, 2014 ... and become thirsty. In winter, people rarely perspire and ... felt in winter to drink the eight glasses of ... Don’t be fooled, warns fresh water advocate Sharon Kleyne. ... and maintaining daily hydration is just as important.     ...
(Date:11/21/2014)... For many busy people, having their missing or ... of recovery from dental surgery that have traditionally been required ... of their youthful appearance. , But the dental implant ... and Woodland Hills, Calif., can provide someone with a full ... where the patient’s bone has deteriorated. , Dr. Saj Jivraj ...
(Date:11/21/2014)... (PRWEB) November 21, 2014 CDT ... the dental practice. It includes everything needed to process ... Procedure Coding with CDT , CDT 2015 codes are ... January 1, 2014 - December 31, 2014. Dental professionals ... and services on dental claims. There are significant changes ...
(Date:11/21/2014)... November 21, 2014 Even with years of ... to learn and room for growth, participating in two recent ... State Farm’s National Convention, a networking event with the leaders ... country, bringing back the latest and greatest in insurance news ... spotted Kirk and his team (Stacy, Anthony, Reina and Jacob) ...
(Date:11/21/2014)... November 21, 2014 CARE Surrogacy Center ... intended parents — and at the same time enhancing their ... of optimism for future parents across the globe, the company ... Prospective parents today are zoning in on the skyrocketing costs ... encumbering costs, are individuals over-stressing clinical success rates ? ...
Breaking Medicine News(10 mins):Health News:Our Bodies Need Eight Glasses of Water a Day Even in Winter Reports Fresh Water Advocate 2Health News:Our Bodies Need Eight Glasses of Water a Day Even in Winter Reports Fresh Water Advocate 3Health News:Anacapa Dental Art Institute Prosthodontists Develop New Technique to Offer Younger Appearance in Just One Visit 2Health News:Anacapa Dental Art Institute Prosthodontists Develop New Technique to Offer Younger Appearance in Just One Visit 3Health News:Anacapa Dental Art Institute Prosthodontists Develop New Technique to Offer Younger Appearance in Just One Visit 4Health News:Anacapa Dental Art Institute Prosthodontists Develop New Technique to Offer Younger Appearance in Just One Visit 5Health News:PMIC Announces CDT PLUS! 2015, the Ultimate Coding Reference for Dentists and Oral Surgeons 2Health News:Kirk Martin Insurance Agency Goes Local and National with State Farm 2Health News:CARE Surrogacy Center Reports on its Multiple Measures of Success 2Health News:CARE Surrogacy Center Reports on its Multiple Measures of Success 3
... energy sources to the eye may help delay retinal ... The transporters, SMCT1 and SMCT2, can circumvent the eyes ... bodies to a healthy eye, says Dr. Pamela Martin, ... diabetes, characterized by plenty of glucose but the inability ...
... Study supports effectiveness of the ultrasound-guided technique , ... minimally invasive procedure is a quick, inexpensive way ... report. , The researchers used ultrasound-guided percutaneous (through ... more than 2,000 people (average age 42) with ...
... Using a novel imaging technique to study autistic ... brain areas that govern social processing and learning by ... J. Lindner Center for Autism, North Shore-Long Island Jewish ... the annual meeting of the Radiological Society of North ...
... 28, 2007 (Oakland, CA) The National Heart ... over the next five years to establish a ... will leverage the collective cardiovascular expertise, diverse community-based ... Kaiser Permanente and eight other health plans in ...
... Card System to Revolutionize Adult Sexual Behaviors, ... Inc.,(SSPB) announced today it will launch the world,s ... Safe Sex Passport (SSP) on December,1st, in conjunction ... the,spread of Sexually Transmitted Diseases (STDs) by providing ...
... pleased to,announce that Gail Oliver has been named Vice ... this position, Ms. Oliver will lead,and manage the Loss ... development opportunities for this aspect of the,company,s portfolio., ... years. Most recently, she,has been serving as the Regional ...
Cached Medicine News:Health News:Transporters may help delay diabetes-related retinal damage 2Health News:Transporters may help delay diabetes-related retinal damage 3Health News:Saline Wash May Ease Shoulder Tendonitis 2Health News:Novel imaging technique shows gray matter increase in brains of autistic children 2Health News:National Heart Lung and Blood Institute creates national network to study cardiovascular disease 2Health News:Safe Sex Passport Launches to Provide Breakthrough Protection Against STDs and HIV 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: